Mon - Fri 9.00 - 17.00 Sat - Sun CLOSED

0161 358 1395

Top
Melissa Pyle Archives - Psychosis Research Unit
fade
208
archive,category,category-melissa-pyle,category-208,mkdf-boxed,wellspring-ver-1.8,mkdf-smooth-scroll,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-fixed-on-scroll,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-top,mkdf-full-width-wide-menu,mkdf-search-dropdown,wpb-js-composer js-comp-ver-4.12,vc_responsive

Melissa Pyle

Measuring Common Responses to Psychosis: Assessing the Psychometric Properties of a New Measure

Sarah Tully, Adrian Wells, Melissa Pyle, Jemma Hudson, Andrew Gumley, David Kingdon, Matthias Schwannauer, Douglas Turkington, Anthony P. Morrison Full Article  Abstract Responses to psychotic experiences are central to cognitive models of psychosis. The current study aimed to develop and validate a self-report measure of common responses to the experience of psychosis. This measure is needed as cognitive and behavioural responses are implicated in the maintenance of psychosis, but there is currently no measure that comprehensively assesses these maintaining factors. The Measure of Common Responses to psychosis (MCR) was developed and utilised in a sample of 487 participants who met criteria for treatment-resistant schizophrenia. Principal components analysis using data from 287 participants reduced the initial item pool of 31 items to 15 items with a three...

Share

Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial

Melissa Pyle, John Norrie, Matthias Schwannauer, David Kingdon, Andrew Gumley, Douglas Turkington, Rory Byrne, Suzy Syrett, Graeme MacLennan, Robert Dudley, Hamish J. McLeod, Helen Griffiths, Samantha Bowe, Thomas R. E. Barnes, Paul French, Paul Hutton, Linda Davies and Anthony P. Morrison Full Article Abstract Background For around a third of people with a diagnosis of schizophrenia, the condition proves to respond poorly to treatment with many typical and atypical antipsychotics. This is commonly referred to as treatment-resistant schizophrenia. Clozapine is the only antipsychotic with convincing efficacy for people whose symptoms are considered treatment-resistant to antipsychotic medication. However, 30–40 % of such conditions will have an insufficient response to the drug. Cognitive behavioural therapy has been shown to be an effective treatment for schizophrenia when delivered in combination with antipsychotic medication, with several meta-analyses showing robust support for this approach. However, the evidence for the effectiveness of cognitive behavioural therapy for...

Share

A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: rationale, study design and baseline data of the COMPARE trial

Heather Law, Lucy Carter, Rachel Sellers, Richard Emsley, Rory Byrne, Linda Davies, Paul French, Peter M. Haddad, Elizabeth Pitt, Melissa Pyle, David Shiers, Alison R. Yung & Anthony P. Morrison Full Article Abstract Aims: Ongoing NICE guidance recommends research on the clinical and cost effectiveness of psychological treatment alone, compared to antipsychotic medication and compared to psychological treatment and antipsychotic medication combined. The COMPARE study (Cognitive behaviour therapy or Medication for Psychosis- A Randomised Evaluation) was a pilot trial designed to inform a definitive trial to answer this question. Method: COMPARE was a single-site pilot randomised controlled trial to compare a standardised Cognitive Behaviour Therapy (CBT) intervention to treatment with antipsychotic medication (APs) and a combined treatment (CBT plus APs) in adults with psychosis. Participants were assessed using...

Share